Published in Int J Cancer on October 31, 2013
Effect of Fee on Attendance in Cervical Cancer Screening | NCT02378324
Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer (2014) 0.95
Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme. PLoS One (2016) 0.86
Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program. BMC Cancer (2016) 0.78
Self-sampling in cervical cancer screening: comparison of a brush-based and a lavage-based cervicovaginal self-sampling device. BMC Cancer (2016) 0.77
Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms. Int J Cancer (2017) 0.76
The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland. BMC Womens Health (2015) 0.75
Effect of Fee on Cervical Cancer Screening Attendance-ScreenFee, a Swedish Population-Based Randomised Trial. PLoS One (2016) 0.75
The cost-effectiveness of cervical self-sampling to improve routine cervical cancer screening: The importance of respondent screening history and compliance. Cancer Epidemiol Biomarkers Prev (2016) 0.75
PREVALENCE OF HUMAN PAPILLOMAVIRUS IN SELF-TAKEN SAMPLES FROM SCREENING NON-ATTENDERS. J Clin Microbiol (2017) 0.75
Rapid review of evaluation of interventions to improve participation in cancer screening services. J Med Screen (2016) 0.75
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol (2006) 7.13
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med (2007) 5.57
Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int (2011) 3.28
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst (2008) 3.24
Advanced maternal age and adverse perinatal outcome. Obstet Gynecol (2004) 3.01
Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol (2011) 2.81
The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int (2009) 2.63
Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol (2008) 2.41
Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol (2009) 2.33
2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol (2012) 2.32
Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst (2009) 2.32
National community prevalence of overactive bladder in the United States stratified by sex and age. Urology (2011) 2.18
Screening and cervical cancer cure: population based cohort study. BMJ (2012) 1.99
Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ (2007) 1.97
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol (2012) 1.95
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception (2006) 1.90
A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol (2009) 1.86
Effects coding in discrete choice experiments. Health Econ (2005) 1.82
Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ (2010) 1.80
Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. J Clin Epidemiol (2002) 1.79
Influence of smoking, coffee, and tea consumption on bladder pain syndrome in female twins. Urology (2011) 1.59
A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause (2002) 1.57
Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open (2012) 1.51
Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int (2006) 1.50
Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). Eur Urol (2006) 1.43
The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int (2009) 1.40
[In Process Citation]. Lakartidningen (2015) 1.38
The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int (2011) 1.38
Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases International Symposium on Epidemiologic Issues in Urinary Incontinence in Women. Am J Obstet Gynecol (2003) 1.37
Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm (2014) 1.36
The economic impact of overactive bladder syndrome in six Western countries. BJU Int (2009) 1.29
Influenza pandemic: perception of risk and individual precautions in a general population. Cross sectional study. BMC Public Health (2007) 1.24
Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years. Eur Urol (2010) 1.20
Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand (2012) 1.20
Danish GPs' perception of disease risk and benefit of prevention. Fam Pract (2002) 1.19
Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol (2005) 1.18
Preference heterogeneity and choice of cardiac rehabilitation program: results from a discrete choice experiment. Health Policy (2007) 1.15
Sentinel-base DNA genotyping using multiple sequencing primers for high-risk human papillomaviruses. Mol Cell Probes (2006) 1.15
International comparison of the definition and the practical application of health technology assessment. Int J Technol Assess Health Care (2005) 1.14
Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int (2008) 1.12
Women's experience of coping with a positive Pap smear: A register-based study of women with two consecutive Pap smears reported as CIN 1. Acta Obstet Gynecol Scand (2003) 1.12
Evidence for a secular trend in menopausal age: a population study of women in Gothenburg. Menopause (2003) 1.12
Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey. BMC Med Inform Decis Mak (2007) 1.11
Insensitivity to scope in contingent valuation studies: reason for dismissal of valuations? Appl Health Econ Health Policy (2012) 1.08
Laypersons' understanding of relative risk reductions: randomised cross-sectional study. BMC Med Inform Decis Mak (2008) 1.07
A review of adherence to drug therapy in patients with overactive bladder. BJU Int (2008) 1.06
Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand (2002) 1.06
The current and future burden and cost of overactive bladder in five European countries. Eur Urol (2006) 1.06
Conjoint analysis. The cost variable: an Achilles' heel? Health Econ (2003) 1.06
Knowledge and attitudes about the Pap-smear screening program: a population-based study of women aged 20-59 years. Acta Obstet Gynecol Scand (2002) 1.05
Waist circumference and body mass index as predictors of health care costs. PLoS One (2008) 1.05
Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice. Br J Gen Pract (2014) 1.05
Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur Urol (2010) 1.04
The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int (2011) 1.03
Preference for practice: a Danish study on young doctors' choice of general practice using a discrete choice experiment. Eur J Health Econ (2013) 1.03
Time-trends in health technology assessments: an analysis of developments in composition of international health technology assessments from 1989 to 2002. Int J Technol Assess Health Care (2005) 1.02
Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program : a prospective randomized study. Cancer (2007) 0.99
Overactive bladder syndrome in older people. BJU Int (2007) 0.99
Ordering effect and price sensitivity in discrete choice experiments: need we worry? Health Econ (2006) 0.99
Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn (2010) 0.98
Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial. Int J Cancer (2013) 0.98
Comparing hospital costs: what is gained by accounting for more than a case-mix index? Soc Sci Med (2009) 0.96
Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med (2008) 0.95
Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer (2007) 0.95
Oestrogens and overactive bladder. Neurourol Urodyn (2013) 0.94
UR-CHOICE: can we provide mothers-to-be with information about the risk of future pelvic floor dysfunction? Int Urogynecol J (2014) 0.93
Do general practitioners know patients' preferences? An empirical study on the agency relationship at an aggregate level using a discrete choice experiment. Value Health (2012) 0.93
Estimating the Danish populations' preferences for pharmacogenetic testing using a discrete choice experiment. The case of treating depression. Value Health (2008) 0.93
The performance of a new scoring system for colposcopy in detecting high-grade dysplasia in the uterine cervix. Acta Obstet Gynecol Scand (2005) 0.93
The relationship between BMI and urinary incontinence subgroups: results from EpiLUTS. Neurourol Urodyn (2013) 0.93
Organisational determinants of production and efficiency in general practice: a population-based study. Eur J Health Econ (2011) 0.92
Estimating a WTP-based value of a QALY: the 'chained' approach. Soc Sci Med (2013) 0.91
Can we prevent incontinence? ICI-RS 2011. Neurourol Urodyn (2012) 0.91
General practitioners' preferences for the organisation of primary care: a discrete choice experiment. Health Policy (2012) 0.90
Rationale for the study methods and design of the epidemiology of lower urinary tract symptoms (EpiLUTS) study. BJU Int (2009) 0.90
Genetics and the lower urinary tract. Neurourol Urodyn (2010) 0.90
Short- and long-term results of the tension-free vaginal tape procedure in the treatment of female urinary incontinence. Acta Obstet Gynecol Scand (2006) 0.90
Communicating effectiveness of intervention for chronic diseases: what single format can replace comprehensive information? BMC Med Inform Decis Mak (2008) 0.89
Risk of urinary incontinence symptoms in oral contraceptive users: a national cohort study from the Swedish Twin Register. Fertil Steril (2008) 0.89
Examining lower urinary tract symptom constellations using cluster analysis. BJU Int (2008) 0.88
Contraceptive use and pregnancy outcome in three generations of Swedish female teenagers from the same urban population. Contraception (2009) 0.87
Communicating treatment effectiveness in the context of chronic disease processes. Expert Rev Pharmacoecon Outcomes Res (2006) 0.87
Willingness to pay for allergy-vaccination among Danish patients with respiratory allergy. Int J Technol Assess Health Care (2010) 0.87
The effect of combined oral contraceptives and age on dysmenorrhoea: an epidemiological study. Hum Reprod (2012) 0.86
Trends in time to invasive examination and treatment from 2001 to 2009 in patients admitted first time with non-ST elevation myocardial infarction or unstable angina in Denmark. BMJ Open (2014) 0.86
Expectant management of first-trimester miscarriage in clinical practice. Acta Obstet Gynecol Scand (2003) 0.86
Genetic influences are important for most but not all lower urinary tract symptoms: a population-based survey in a cohort of adult Swedish twins. Eur Urol (2011) 0.85
Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception (2007) 0.85
Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. Am J Obstet Gynecol (2009) 0.85
The long-term influence of combined oral contraceptives on body weight. Hum Reprod (2011) 0.85
Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol (2011) 0.85
Do informal caregivers in mental illness feel more burdened? A comparative study of mental versus somatic illnesses. Scand J Public Health (2011) 0.84
Medication effectiveness may not be the major reason for accepting cardiovascular preventive medication: a population-based survey. BMC Med Inform Decis Mak (2012) 0.84
The genetic and environmental contribution to the occurrence of bladder pain syndrome: an empirical approach in a nationwide population sample. Eur Urol (2010) 0.83
The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med (2011) 0.83